Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Al Mayadeen's correspondent: Two were martyred in an initial toll of the Israeli drone strike that targeted the al-Asira neighborhood in the city of Baalbek, eastern Lebanon
Al Mayadeen's correspondent: An Israeli drone strike targeted the al-Asira neighborhood east of Baalbek, eastern Lebanon
Sheikh Naim Qassem to the pager attack survivors: You are the greatest resistance. Know that 'Israel' will fall because it embodies aggression, crime, and occupation; victory is truly yours
Sheikh Qassem to the pager attack survivors: The value of what you are doing despite your wounds is immense, and here you are, treading the path of the Master of Nation's Martyrs and the leaders
Sheikh Qassem to the pager attack survivors: You are moving forward with insight deeper than sight itself. The enemy sought to eliminate your role in the battle, yet you remain steadfast and continue the fight
Hezbollah Secretary-General Sheikh Naim Qassem to the pager attack survivors one year later: You are healing from your wounds and rising above them. You have successfully passed the test
Palestinian media: Reports of stabbing operation in occupied al-Quds.
Israeli media: Sirens blare in Arava in South, near Ramon Airport.
Egyptian PM Mostafa Madbouli: Egypt is targeted in plans to redraw regional map
AEOI Chief Mohammad Eslami: Our presence in IAEA General Council and fact-checking helped in preventing unilateral rhetoric that aims to portray Iran as an unregulated country

Trikafta, an inaccessible medical 'miracle': NYT

  • By Al Mayadeen English
  • Source: The New York Times
  • 13 Feb 2023 14:26
5 Min Read

Developing countries call on Vertex Pharmaceuticals to allow the sale of Trikafta in poorer countries.

  • x
  • Vihaan doing physiotherapy after a session with the nebulizer. (NYT)
    Young Vihaan doing physiotherapy after a session with the nebulizer. February 8, 2023. (NYT)

An exclusive report by The New York Times (NYT) discussed on Monday a new cystic fibrosis drug by Vertex Pharmaceuticals, a sizable biotech company with headquarters in Boston. However, the drug manufacturer has prevented developing countries from purchasing the drug.

The company has no plans to market it or give a local company permission to produce it. Vertex is preventing potential generic competitors by requesting patents in numerous countries, according to NYT.

Seshagiri Buddana, whose son, Hemanth, has spent a large portion of his childhood in a hospital bed, was hopeful when he learned of the new drug that was changing lives in the United States and Europe, according to NYT, but the family was unable to obtain the drug because they live in India.

According to the newsletter, Hemanth died in December, 18 months after he would have been eligible for the drug known as Trikafta if he had lived in the United States.

Families are watching Trikafta transform the lives of tens of thousands of cystic fibrosis patients in wealthy nations, but they say the company is blocking them at every turn in their efforts to obtain the drug themselves.

What is Trifakta? 

Trikafta is the most potent and widely used of Vertex's four cystic fibrosis medications, taking three tablets per day. It is expected to cost millions of dollars over the course of a patient's lifetime, with a list price of more than $322,000 in the United States, according to NYT. 

An analysis led by British researchers discovered that a year's supply of the drug could be manufactured for as little as $5,700. Since Trikafta was approved in 2019, Vertex has reported more than $17 billion in sales.

The people call for Trikafta 

This week, a group of patients and their families in four countries across four continents took legal and regulatory steps to force their governments to waive intellectual property protections and allow a low-cost generic version of Trikafta to be imported or manufactured locally.

Generic manufacturers would pay Vertex a royalty under the compulsory licensing process.

Three of the actions are in India, Ukraine, and South Africa, where patients and families claim Vertex has been obstructing efforts to make the drug available. The fourth is in Brazil, where Vertex is attempting to secure coverage for the drug; where patients and families are concerned that the brand-name drug will be prohibitively expensive.

What is Cystic fibrosis?

Cystic fibrosis is a genetic disorder that causes lung and digestive system damage. Patients typically die in their early twenties, but Trikafta is significantly extending life expectancy, according to NYT. 

“Every patient in the world has access to the internet and wants this drug,” Christine Noke, a patient advocate in Turkey, said.

Theoretically speaking, reaching patients in developing countries would increase revenue for a pharmaceutical company. However, some manufacturers refuse to lower prices in poorer countries because that will prevent them from charging higher prices in high-income countries.

That said, Vertex, which has a monopoly on transformative cystic fibrosis drugs, stated that it is working to increase global access.

“Our teams are working every day to expand access to even more patients around the world through a range of routes, including in low-middle-income countries and low-income countries where access barriers are high due to challenging economic conditions and limited health care infrastructure,” Heather Nichols, a spokesperson for Vertex, said.

According to Nichols, Vertex has started a "product donation program" in low-income countries. She stated that the company has made at least one of its cystic fibrosis drugs available in Brazil, Poland, Bulgaria, Estonia, Greece, Latvia, Slovakia, Slovenia, Romania, and Oman, according to NYT. However, the company declined to specify which countries with limited resources have access to Trikafta.

Poorer countries deprived of Trikafta

Usually, it takes longer for new drugs to reach poorer countries. but cystic fibrosis patients banded together online and launched a coordinated campaign for mandatory licensing to access the drug. 

Governments are frequently hesitant to implement compulsory licensing, which capital markets see as an alarming breach in the wall of intellectual property protection. Even if governments refuse to issue a mandatory license, patient protests may put pressure on Vertex to make Trikafta available in those countries.

It is worth noting that prior to Vertex's drugs, patients had few options other than palliative treatment to help them breathe a little easier and, if available, a lung transplant. Vertex's drugs addressed the underlying cause of the illness by preventing sludgy mucus from clogging patients' lungs. 

For patients, Trikafta is a phenomenally effective treatment for improving breathing, keeping them out of the hospital, and extending their lives. According to patients and doctors, the drug's effectiveness is apparent almost immediately.

According to NYT, the difficulties in obtaining Trikafta in the developing world extend beyond the product's availability. A large number of patients are still undiagnosed and those who are diagnosed are unlikely to be able to afford the costly genetic testing required to determine whether they have one of the mutations required for the drug to work.

Moreover, the most common mutation required for the drug to work is found in approximately 90% of patients of Northern European ancestry, compared to far fewer people from the Middle East, Asia, and Africa. Estimates in India range from 19 to 44 percent, according to the NYT report. 

Read next: New cystic fibrosis treatment may end suffering for patients

  • Trikafta
  • Vertex Pharmaceuticals
  • pharmaceuticals
  • Medicine
  • cystic fibrosis

Most Read

Uprising against Volker Turk at the Human Rights Council over Gaza.

Uprising against Volker Turk at the Human Rights Council over Gaza

  • Politics
  • 12 Sep 2025
A screengrab from the ad played on Fox News. (X Screengrab)

Fox airs ad warning Trump not to let Netanyahu 'play' him on Gaza

  • US & Canada
  • 11 Sep 2025
Lapid: Egypt’s Arab Force plan a 'severe blow' to normalization

Lapid: Egypt’s Arab Force plan a 'severe blow' to normalization

  • Palestine
  • 14 Sep 2025
UKLFI’s latest faux pas, like "Israel’s" recent failed attempt at regime change in Iran, is unambiguously indicative of a flailing entity on the verge of extinction. (Al Mayadeen English; Illustrated by Zeinab el-Hajj)

Zionist lawfare operation facing collapse?

  • Opinion
  • 13 Sep 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
A Hezbollah supporter who lost his sight in a pager attack carried out by "Israel" on Sept. 17, 2024, covers his eyes with a red headband inscribed with the name "Hussein" during Ashoura, July 6, 2025 (AP)
Politics

'We Have Recovered': Lebanon marks 1st anniversary of Pager Attack

The Arab neighborhood of El Za'im, on the outskirts of east Occupied Al-Quds in the West Bank, near where Israeli government says housing units will be built as part of the E1 settlement project, Thursday, August 21, 2025. (AP Photo/Ohad Zwigenberg)
Palestine

'Israel’s' deliberate policies drive West Bank economy toward collapse

Ben & Jerry's ice cream shop, Wednesday, Feb. 26, 2025, in Cambridge, Mass. (AP Photo/Charles Krupa)
Politics

Ben & Jerry’s co-founder resigns over parent company curbing activism

Trump’s approval rating falls to new low in second term: Poll
US & Canada

Trump’s approval rating falls to new low in second term: Poll

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS